Israeli med-tech company InSightec Image Guided Treatment has announced that it has been approved for US Food and Drug Administration (FDA) premarketing of its ExAblate targeted focused ultrasound treatment for the removal of bone tumors.
According to Globes online business magazine, the initial approval is for patients who cannot or will not undergo radiation therapy.
According to InSightec, 30% of bone cancer patients cannot undergo radiation treatment.
InSightec is controlled by Elbit Medical Technologies.Malkah Fleisher
About the Author: Malkah Fleisher is a graduate of Cardozo Law School in New York City. She is an editor/staff writer at JewishPress.com and co-hosts a weekly Israeli FM radio show. Malkah lives with her husband and two children on the Mount of Olives in Jerusalem.
If you don't see your comment after publishing it, refresh the page.